ADIL Adial Pharmaceuticals, Inc. Stock Quote

ADIL [NASD]

Index	-	P/E	-	EPS (ttm)	-0.82	Insider Own	17.53%	Shs Outstand	13.65M	Perf Week	-0.52%
Market Cap	26.36M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-12.69%	Shs Float	11.87M	Perf Month	3.23%
Income	-9.50M	PEG	-	EPS next Q	-0.25	Inst Own	9.80%	Short Float	2.84%	Perf Quarter	-2.54%
Sales	-	P/S	-	EPS this Y	64.30%	Inst Trans	0.07%	Short Ratio	0.50	Perf Half Y	35.21%
Book/sh	0.52	P/B	3.69	EPS next Y	28.10%	ROA	-121.30%	Target Price	-	Perf Year	-11.52%
Cash/sh	0.54	P/C	3.56	EPS next 5Y	-	ROE	-132.80%	52W Range	1.00 - 4.00	Perf YTD	12.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-52.00%	Beta	-
Dividend %	-	Quick Ratio	7.50	Sales past 5Y	-	Gross Margin	-	52W Low	92.00%	ATR	0.14
Employees	3	Current Ratio	7.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.21	Volatility	8.92% 6.60%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-46.10%	Profit Margin	-	Rel Volume	0.49	Prev Close	2.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	673.56K	Price	1.92
Recom	2.00	SMA20	3.34%	SMA50	2.40%	SMA200	18.36%	Volume	328,438	Change	-6.80%

Oct-30-18

Initiated

Maxim Group

Buy

Oct-11-18

Initiated

Dawson James

Buy

Jan-11-21 11:00AM	Adial Pharmaceuticals to Present at 23rd Annual ICR Conference ACCESSWIRE +7.25%
09:50AM	Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder ACCESSWIRE
Dec-17-20 09:45AM	Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Dec-15-20 09:30AM	Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory ACCESSWIRE
Dec-10-20 12:10PM	Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments ACCESSWIRE
09:30AM	Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction ACCESSWIRE
Dec-09-20 11:25AM	Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley ACCESSWIRE
Dec-04-20 09:30AM	Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured in Follow-up TV News Story ACCESSWIRE
Nov-25-20 12:20PM	Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured on Multiple Television News Outlets ACCESSWIRE
09:30AM	Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives ACCESSWIRE
Nov-16-20 05:33AM	We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully Simply Wall St. -6.52%
Nov-03-20 09:50AM	Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder ACCESSWIRE
Oct-22-20 09:30AM	Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep(R) Point-of-Care Covid-19 Antibody Tests ACCESSWIRE +12.87%
08:30AM	Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices GlobeNewswire
08:30AM	Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices ACCESSWIRE
Oct-21-20 09:30AM	Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder ACCESSWIRE
Sep-30-20 09:25AM	Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices ACCESSWIRE -26.40%
Sep-29-20 09:30AM	Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples ACCESSWIRE +114.89%
Sep-25-20 10:00AM	Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA ACCESSWIRE
Sep-22-20 09:30AM	Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales ACCESSWIRE
Sep-09-20 09:00AM	Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th ACCESSWIRE
Sep-01-20 07:22PM	Adial Pharmaceuticals to Present at The LD Micro 500 Virtual Conference on September 2nd ACCESSWIRE +8.70%
Aug-31-20 05:00PM	LD Micro - 360 Companies Set to Present this Week ACCESSWIRE
Aug-06-20 09:30AM	Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits ACCESSWIRE +14.97%
Aug-05-20 09:00AM	LD Micro Announces Preliminary List of Presenters for the LD 500 ACCESSWIRE
Jul-28-20 09:30AM	Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call ACCESSWIRE
Jul-22-20 09:45AM	Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder ACCESSWIRE
Jul-06-20 08:15AM	Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia ACCESSWIRE
Jun-25-20 09:30AM	Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland ACCESSWIRE +5.71%
Jun-17-20 09:55AM	Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia ACCESSWIRE
Jun-15-20 09:30AM	Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering ACCESSWIRE
Jun-11-20 11:35AM	Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland ACCESSWIRE -7.01%
Jun-10-20 10:06AM	Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits ACCESSWIRE +8.28%
Jun-09-20 09:15AM	Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market ACCESSWIRE -28.57%
Jun-08-20 09:30AM	Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests ACCESSWIRE +18.00%
May-28-20 09:30AM	Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors ACCESSWIRE
May-04-20 10:15AM	Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress ACCESSWIRE
Apr-23-20 08:45AM	Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility ACCESSWIRE
Apr-16-20 10:17AM	Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial ACCESSWIRE +18.84%
Apr-15-20 09:45AM	Adial Pharmaceuticals Issued Second Patent Covering AD04 as a Treatment for Opioid Use Disorder ACCESSWIRE
Apr-09-20 09:30AM	Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial ACCESSWIRE
Mar-29-20 08:19AM	Will Adial Pharmaceuticals (NASDAQ:ADIL) Spend Its Cash Wisely? Simply Wall St.
Mar-26-20 09:15AM	Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder ACCESSWIRE
Mar-17-20 09:30AM	Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19 ACCESSWIRE
Feb-19-20 09:37AM	Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria ACCESSWIRE +6.19%
Feb-14-20 09:15AM	Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat ACCESSWIRE -9.82%
Feb-06-20 12:30PM	Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder ACCESSWIRE +8.82%
Jan-09-20 09:15AM	Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland ACCESSWIRE
Dec-30-19 05:36AM	Need To Know: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Insiders Have Been Buying Shares Simply Wall St. +7.75%
Dec-19-19 09:30AM	Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries ACCESSWIRE +6.55%
Dec-16-19 09:00AM	Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker ACCESSWIRE +15.00%
Dec-13-19 09:30AM	Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial ACCESSWIRE +30.95%
Oct-29-19 08:30AM	Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites ACCESSWIRE -5.20%
Oct-17-19 10:30AM	Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker ACCESSWIRE
Oct-07-19 09:26AM	Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Oct-01-19 08:30AM	Adial Files Clinical Trial Application to Commence Phase 3 Trial ACCESSWIRE
Sep-27-19 11:52AM	We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-25-19 09:50AM	Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019 ACCESSWIRE
Sep-11-19 09:15AM	Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial ACCESSWIRE +5.73%
Sep-07-19 09:30AM	Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Aug-06-19 04:30PM	Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell'' ACCESSWIRE
Jul-29-19 03:01PM	Do Directors Own Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares? Simply Wall St.
Jun-19-19 09:00AM	Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare ACCESSWIRE -5.56%
Jun-13-19 09:35AM	Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder ACCESSWIRE +7.29%
Jun-06-19 09:00AM	Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization ACCESSWIRE +6.77%
May-07-19 09:00AM	Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder ACCESSWIRE
Apr-30-19 09:00AM	Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City ACCESSWIRE
Apr-29-19 11:56AM	Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year? Simply Wall St.
Apr-22-19 09:00AM	Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate ACCESSWIRE
Apr-11-19 09:00AM	Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy ACCESSWIRE
Apr-04-19 09:00AM	Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award ACCESSWIRE
Apr-03-19 09:00AM	Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. ACCESSWIRE
Mar-26-19 09:00AM	Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer ACCESSWIRE
Mar-25-19 08:00AM	Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants ACCESSWIRE
Feb-28-19 03:02PM	Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner Benzinga
09:15AM	Adial Pharmaceuticals Featured on CBS in San Francisco GlobeNewswire
Feb-26-19 08:00AM	Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters Over-Allotment Option GlobeNewswire -7.05%
Feb-21-19 01:35PM	Four Biotech Stocks Setting The Standard On Thursday (2/21/19) ACCESSWIRE +17.80%
08:45AM	Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering GlobeNewswire
Feb-20-19 09:00AM	Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adials AD04 for its Phase 3 Trial GlobeNewswire -6.13%
Feb-15-19 08:30AM	Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse GlobeNewswire
Feb-12-19 09:33AM	Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -9.71%
Feb-07-19 09:15AM	Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award GlobeNewswire
Feb-01-19 09:20AM	Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder GlobeNewswire +25.78%
Jan-24-19 08:30AM	Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants GlobeNewswire +10.19%
Jan-23-19 01:57PM	What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)? Simply Wall St. -6.90%
Jan-17-19 09:00AM	Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -6.58%
Jan-15-19 09:05AM	Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series GlobeNewswire +14.58%
Jan-10-19 08:00AM	Adial Pharmaceuticals to Present at The 2019 Wall Street Conference GlobeNewswire +12.07%
Dec-27-18 10:25AM	These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE -8.40%
Dec-26-18 04:18PM	Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today InvestorPlace +27.47%
11:57AM	4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018 ACCESSWIRE
07:30AM	Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 08:00AM	Adial Pharmaceuticals Retires All Outstanding Debt GlobeNewswire +15.12%
07:30AM	Biotech Breakout Candidates ACCESSWIRE
Dec-20-18 06:50AM	Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE -15.66%
Dec-19-18 09:00AM	Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group GlobeNewswire +23.39%
Dec-14-18 06:55AM	Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics ACCESSWIRE -8.65%
Dec-13-18 12:49PM	Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today InvestorPlace +104.93%
08:00AM	Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl GlobeNewswire

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnson Bankole A.	Chief Medical Officer	Aug 20	Sale	1.21	350,000	423,500	1,055	Aug 24 04:59 PM
Newman James W. Jr.	Director	Mar 27	Buy	1.34	14,644	19,669	14,644	Mar 30 09:23 AM
Newman James W. Jr.	Director	Mar 27	Buy	1.42	5,000	7,100	15,000	Mar 30 09:23 AM
Stilley William B. III	Chief Executive Officer	Mar 26	Buy	1.47	12,652	18,598	715,937	Mar 27 06:03 AM
Stilley William B. III	Chief Executive Officer	Mar 25	Buy	1.13	12,348	13,953	703,285	Mar 27 06:03 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience